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ABSTRACT 
Two simple and economical UV spectroscopic methods were developed for the estimation of Luliconazole in creams. The drug showed 
maximum absorption at 294 nm, both in 0.1N HCl and phosphate buffer (pH 2.0) in the fundamental spectra (D0). The same spectra were 
derivatized into first derivative (D1) and the dA/dλ was measured at 315 nm in 0.1N HCl and 317 nm in phosphate buffer (pH 2.0). In both the 
methods the drug obeyed Beer-Lambert’s law in the concentration range of 2-30 μg/mL in 0.1N HCl and 10-30 μg/mL in phosphate buffer (pH 
2.0). The linear regression equations were calculated to be y = 0.0504x + 0.0102 (R2 = 0.9991) for D0 and y = 0.0025x + 0.0002 (R2 = 0.9991) for 
D1 in 0.1N HCl, y = 0.0637x + 0.0181 (R2 = 0.999) for D0 and y = 0.0025x + 0.0006 (R2 = 0.999) for D1 in phosphate buffer (pH 2.0). An acceptable 
recovery in the range of 98 ± 0.01 – 102 ± 0.001 % indicates accuracy as well as non-interference from excipients in the present method. The 
intraday and inter day precision results were within 2 % RSD indicating the preciseness of the methods. The methods were applied for 
quantification of Luliconazole in marketed creams and the assay was obtained as 98.53 % w/w against the label claim. The methods were also 
applied to study the stability aspects of the drug in a variety of conditions like acid, base and oxidative stress along with thermal and photolytic 
stress conditions. The drug showed altered absorbance in basic and photolysis conditions. The methods were validated statistically as per the 
ICH guidelines. 
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INTRODUCTION 
Luliconazole (LCZ), chemically named as (2E)-2-[(4R)-4-
(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-
ylacetonitrile (Fig.1.) is a broad-spectrum imidazole that is 
active against various fungi including Tinea, Candida, 
Aspergillus, Trichophyton and Epidermophyton. It has a 
molecular formula C14H9Cl2N3S2, molecular weight of 354.28 
and melting point in the range 121-125˚C 1. Luliconazole is 
used for the treatment of interdigital tinea pedis, tinea 
cruris, and tinea corporis 2-3. The mode of action of 
Luliconazole against dermatophytes is unknown, 
Luliconazole appears to inhibit ergosterol synthesis by 
inhibiting the enzyme lanosterol demethylase. Inhibition of 
this enzyme’s activity by azoles results in decreased 
amounts of ergosterol, a constituent of fungal cell 
membranes, and a corresponding accumulation of lanosterol 
4, 5. Luliconazole may be metabolized by CYP2D6 and 3A4 6. 
Luliconazole, an imidazole antifungal medication available 
as a 1% topical cream, is indicated for the treatment of 
athlete's foot, jock itch, and ringworm caused by 
dermatophytes such as Trichophyton rubrum, Microsporum 
gypseum and Epidermophyton floccosum. 
 
Figure1: Structure of Luliconazole 
Review of literature for Luliconazole analysis revealed very 
few methods such as LC-MS/MS 7 method (toe nails) HPLC 
for related substances 8, HPTLC method for assay in 
formulation and biofluid 9, and a single UV spectroscopic 
method 10 (area under curve) have been reported for assay 
Sowjanya et al                                                                                                     Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):300-306 
ISSN: 2250-1177                                                                                  [301]                                                                                 CODEN (USA): JDDTAO 
of Luliconazole. However, there is no simple method 
reported for the detection of the drug in pharmaceutical 
formulation by UV spectrophotometry. So, an attempt has 
been made to establish a simple, fast, accurate and economic 
method for determination of Luliconazole in bulk powder 
and its dosage forms, which can be used in quality control 
laboratories. This paper reports a study on the development 
of new validated UV- spectrophotometric methods for the 
quantitative determination of Luliconazole in creams using 
0.1 N HCl and phosphate buffer (pH 2.0). 
MATERIALS AND METHODS 
A double beam UV-Visible Spectrophotometer (UV-1800 
Shimadzu, Japan) with matching quartz cuvettes was used to 
measure absorbance. All weights were taken on an 
electronic balance (AUX 220 Shimadzu, Japan). 
Reference standard of Luliconazole was obtained as a gift 
sample from Sun Pharma Ltd. and the pharmaceutical 
dosage form (cream, Lulifin®) containing 1% w/w of 
Luliconazole was procured from local pharmacy. 
Hydrochloric acid, sodium hydroxide, hydrogen peroxide, 
potassium dihydrogen phosphate (AR grade) were procured 
from Qualigens and distilled water was used throughout the 
study. 
Preparation of calibration curve: A stock solution was 
prepared by dissolving 10.0 mg of Luliconazole in 10 mL of 
methanol in a suitable volumetric flask (1000 µg/mL). 
Working standard solutions of Luliconazole were prepared 
by pipetting 1mL of stock solution and diluting to 10 mL 
with 0.1N HCl and phosphate buffer (pH 2.0) in separate 
volumetric flasks (100 µg/mL). Further dilutions were made 
by transferring suitable aliquots (0.2 – 3 mL) into various 10 
mL volumetric flasks and made upto volume with the 
solvents. The resulting solutions were then scanned in the 
UV range (200-400nm) in 10 mm matched quartz cells in a 
UV-Visible double beam spectrophotometer. The drug 
showed maximum absorption at 294 nm in both the 
solvents. The same spectra were derivatized into first 
derivative, the derivative absorbance of minima was 
measured at 315 nm (0.1N HCl) and at 317 nm (phosphate 
buffer, pH 2.0).  
Estimation of Luliconazole in formulation (cream): For 
the analysis of Luliconazole in creams, 0.5mg of cream base 
was taken in a 50 mL volumetric flask, methanol was added 
in increments, the drug was dissolved by constant stirring 
and after complete dissolving of cream base the remaining 
volume was made up with methanol. This solution is filtered 
and from the filtrate suitable aliquots were diluted with 0.1N 
HCl and phosphate buffer (pH 2.0). The absorbance of each 
solution was measured against respective blank at 294 nm. 
Method Validation 
The methods were validated according to International 
Conference of Harmonization (ICH) guidelines for validation 
of analytical procedures 11, 12. 
Linearity 
Standard solutions of Luliconazole were prepared in the 
range of 2-30 μg/mL (0.1N HCl) and 10- 30 μg/mL 
(phosphate buffer, pH 2.0). The absorbance of each solution 
was measured and calibration curves were constructed by 
plotting absorbance versus concentrations. Linearity was 
determined from the regression analysis. 
Accuracy 
It was analysed by percentage recovery of added standard 
drug from bulk to fixed concentration of sample solutions. 
The standard drug was added at 50, 100 and 150% of the 
sample concentration, each solution was prepared in 
triplicate in both the solvents and the absorbance measured 
to find out the percentage recovery.  
Precision 
Repeatability was calculated by analysing three independent 
Luliconazole sample solutions (5, 10, 15 μg/mL), in 
triplicate, in 0.1N HCl and phosphate (pH 2.0). The 
intermediate precision was evaluated on 2 consecutive days. 
The precision was expressed as the percentage relative 
standard deviation (coefficient of variation). 
Limit of detection and limit of quantification 
Limit of detection (LOD) and limit of quantification (LOQ) 
are based on the slope of the calibration curves and standard 
deviation of y-intercepts of regression lines. 
Stability 
 The developed methods were applied for assessing the 
stability related aspects of the drug and so the drug was 
exposed to a series of stress like acidic, basic, oxidative, 
photolytic and thermolytic conditions. Thermal degradation 
and photo degradation of drug substance were carried out in 
solid state. Degradations were performed on a 100 µg/mL 
solution and finally diluted with 0.1N HCl and phosphate 
buffer (pH 2.0) to obtain a concentration of 10 µg/mL.  
Acid hydrolysis in solution state was performed by treating 
1 mL of working standard solution of Luliconazole with 1mL 
of 0.1 N HCl and heated at 60° for 30 minutes.  The drug 
solution was also tested for stability in the acidic medium by 
treating with 1mL of 0.1N HCl and kept aside for one day 
without heating. These solutions were made up to volume 
with 0.1 N HCl and phosphate buffer pH 2.0 for which the 
absorbance was measured.  
Base hydrolysis in solution state was performed by treating 
1 mL of working standard solution of Luliconazole with 1mL 
of 0.1 N NaOH and heated at 60° for 30 minutes.  The drug 
solution was also tested for stability in the basic medium by 
treating with 1mL of 0.1N NaOH and kept aside for one day 
without heating. These solutions were made up to volume 
with 0.1 N HCl and phosphate buffer pH 2.0 for which the 
absorbance was measured.  
For oxidative stress, an aliquot of the working standard 
solution was treated with 1mL of 3% H2O2 and exposed to 
various conditions like room temperature (for 30 min.), 
heating at 60° for 30 minutes and kept aside without heating 
for 1 day.  Finally, the volume was made up with 0.1 N HCl 
and phosphate buffer pH 2.0 and the absorbance was 
measured. 
Photolytic stress was conducted by exposing the drug in 
solid state and also in solution form to UV radiation for 30 
minutes, volume was made up with 0.1 N HCl and phosphate 
buffer pH 2.0 and absorbance measured. 
For thermal stress, solid sample and solution sample of drug 
substances were entrusted in a controlled-temperature oven 
at 80°C for 1 Hr, volume made up with 0.1 N HCl and 
phosphate buffer pH 2.0. 
RESULTS AND DISCUSSION 
An attempt was made to develop simple and economical 
methods for the quantification of Luliconazole in creams. 
Two UV spectroscopic methods (D0 and D1) were developed 
using 0.1N HCl and phosphate buffer (pH 2.0).  In the D0 
method, the drug showed maximum absorption at 294 nm 
and obeyed Beer-Lambert’s law in the concentration range 
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of 2-30 μg/mL for 0.1N HCl and 10-30 μg/mL for phosphate 
buffer (pH 2.0). The same spectra were derivatized into first 
derivative, the absorbance of minima was measured at 315 
nm for 0.1N HCl, at 317 nm for phosphate buffer (pH 2.0) 
and the drug showed linearity in the concentration range 
from 2-30μg/mL for 0.1N HCl and 10-30μg/mL for 
phosphate buffer (pH 2.0). The overlain spectra and 
calibration curves in both the methods are shown in figure 
2,3 and 4,5 respectively. 
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Figure 2: Overlain spectra of Luliconazole in zero order (A) and first order (B) (0.1N HCl) 
Figure 3: Calibration curve of Luliconazole in zero order (A) and first order (B) (0.1N HCl) 
Figure 4: Overlain spectra of Luliconazole in zero order (A) and first order (B) (Phosphate pH 2.0) 
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Figure 5: Calibration curve of Luliconazole in zero order (A) and first order (B) (Phosphate pH 2.0) 
 
The methods were validated in terms of accuracy, precision, 
LOD, LOQ and specificity wherein the results are recorded in 
table 1 to 6. The accuracy of the method was determined by 
performing recovery studies by standard addition method in 
which pre analysed samples were taken and standard drug 
was added at three different levels. Values of recovery ± SD 
in the range of 98.0 % - 102 % indicate that proposed 
method is accurate for the analysis of the drug.  
The precision of the proposed method was estimated in 
terms of inter-day precision and intra-day precision wherein 
the method was repeated on two different days and 
repeated for two different time periods in the same day 
respectively. The results shown in table 3 and 4 indicating 
%RSD less than 2% at each level clearly indicate that the 
proposed method is precise enough for the analysis of the 
drug.
  
Table 1: Recovery studies in 0.1 N HCl 
Level 
Pure drug 
conc. 
(μg/mL) 
Cream conc. 
(μg/mL) 
*Absorbance 
Conc. found 
(μg/mL) 
*Recovery (%) ± SD, 
% RSD 
D0 D1 D0 D1 D0 D1 
50% 2.5 5 0.396 0.018 7.52 7.42 101 ± 0.003, 0.75 99 ± 0.0003, 0.001 
100% 5 5 0.520 0.025 10.11 9.92 102 ± 0.001, 0.19 99 ± 0.0005, 0.019 
150% 7.5 5 0.645 0.125 12.51 12.42 100 ± 0.004, 0.62 98 ± 0.01, 0.01 
* Mean recovery of three determinations 
Table 2: Recovery studies in phosphate pH 2.0 
* Mean recovery of three determinations 
Table 3. Results of method precision in 0.1 N HCl 
Conc. 
(μg/mL) 
INTRA DAY INTER DAY 
*Absorbance 
*Assay (% w/w) ± SD, 
% RSD 
*Absorbance 
*Assay (% w/w) ± SD, 
% RSD 
D0 D1 D0 D1 D0 D1 D0 D1 
5 0.260 0.011 
99.99 ±  
0.02, 0.39 
100 ± 0.02, 
0.39 
0.263 0.010 
99.99 ± 0.02, 
0.39 
99.99 ±  
0.02, 0.39 
10 0.579 0.024 
102 ±  
0.06, 0.53 
101 ± 0.05, 
0.49 
0.580 0.021 
102 ± 0.06, 
0.53 
101 ±  
0.05, 0.49 
15 0.881 0.035 
101 ±  
0.05, 0.38 
100 ± 0.04, 
0.26 
0.890 0.032 
101 ± 0.04, 
0.26 
100 ±  
0.04, 0.26 
* Mean of three determinations 
 
The method was applied to understand the stability aspects 
of the drug in a variety of stress conditions. The drug 
responded to the base stress in 0.1N HCl, base and photolytic 
stress in phosphate pH 2.0. which could be predicted from 
the abnormal change in the assay values. The data is 
mentioned in table 5 and 6, the spectra are given in figure 6, 
7 and 8. 
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Level 
Pure drug 
conc. 
(μg/mL) 
Cream conc. 
(μg/mL) 
*Absorbance 
Conc. found 
(μg/mL) 
*Recovery (%) ±SD,  
%RSD 
D0 D1 D0 D1 D0 D1 
50% 2.5 5 0.48 0.020 7.6 7.4 101 ± 0.01, 1.0 98 ± 0.001, 0.05 
100% 2.5 5 0.62 0.025 10.0 9.92 99.9 ± 0.02, 0.9 99 ± 0.0005, 0.02 
150% 2.5 5 0.79 0.031 12.55 12.42 101 ± 0.01, 1.2 98 ± 0.0005, 0.0006 
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Table 4: Results of method precision in phosphate pH 2.0 
Conc. 
(μg/mL) 
INTRA DAY INTER DAY 
*Absorbance *Assay (w/w) ± SD,  % RSD *Absorbance *Assay (w/w) ± SD, % RSD 
D0 D1 D0 D1 D0 D1 D0 D1 
5 0.275 0.013 
99.99 ± 0.06, 
0.53 
99.99 ± 0.02, 
0.39 
0.278 0.012 
99.99 ± 0.02, 
0.39 
99.99 ±  
0.03, 0.43 
10 0.555 0.025 
102 ± 0.02, 
0.39 
102 ±  
0.05, 0.49 
0.552 0.024 
102 ±  0.06, 
0.53 
101 ±  
0.04, 0.54 
15 0.831 0.033 
101 ± 0.04, 
0.26 
101 ±  
0.04, 0.26 
0.830 0.032 
100 ± 0.04, 
0.26 
101 ±  
0.05, 0.43 
* Mean of three determinations 
Table 5: Stress degradation studies in 0.1N HCl 
Conc. 
(μg/mL) 
Condition 
Absorbance *Assay (w/w) ± SD, %RSD 
D0 D1 D0 D1 
10 
Acid 0.577 0.023 102 ± 0.081; 0.12 100 ± 0.05; 0.49 
Acid heat 0.561 0.025 101.6 ± 0.002; 0.35 102 ± 0.08; 0.51 
10 
Base 0.663 0.024 120 ± 0.001; 0.15 101 ± 0.04; 0.54 
Base heat 0.605 0.029 109 ± 0.003; 0.23 104 ± 0.06; 0.61 
10 
Oxidation 0.542 0.024 100 ± 0.002; 0.20 101 ± 0.04; 0.54 
Oxidation heat 0.593 0.025 102 ± 0.004; 0.43 102 ± 0.08; 0.51 
10 
Thermal 0.542 0.024 100 ± 0.001; 0.29 101 ± 0.04; 0.54 
Thermal(solid) 0.560 0.023 101 ± 0.002; 0.36 100 ± 0.05; 0.49 
10 
Photo 0.503 0.020 98 ± 0.003; 0.13 98 ± 0.03; 0.13 
Photo (solid) 0.541 0.023 100 ± 0.002; 0.16 100 ± 0.05; 0.49 
* Mean of three determinations 
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Figure 6: Base degradation spectra in zero order (A) and first derivative (B) (0.1N HCl) 
 
Table 6: Stress degradation studies of phosphate pH 2.0 
Conc. 
(μg/mL) 
Condition 
*Absorbance 
*Assay (w/w) ± SD 
%RSD 
D0 D1 D0 D1 
10 
Acid 0.534 0.022 100 ± 0.09; 0.12 99 ± 0.03; 0.38 
Acid heat 0.543 0.023 100 ± 0.005; 0.62 100 ± 0.05; 0.49 
10 
Base 0.139 0.004 25 ± 0.002; 0.75 21 ± 0.001; 0.22 
Base heat 0.693 0.029 126 ± 0.008; 0.9 104 ± 0.06; 0.61 
10 
Oxidation 0.555 0.023 101 ± 0.001; 0.21 100 ± 0.05; 0.49 
Oxidation heat 0.572 0.025 102 ± 0.002; 0.15 102 ± 0.08; 0.51 
10 
Thermal 0.566 0.024 102 ± 0.004; 0.17 101 ± 0.04; 0.54 
Thermal(solid) 0.562 0.024 102 ± 0.006; 0.20 101 ± 0.04; 0.54 
10 
Photo 0.638 0.030 114 ± 0.009; 0.15 106 ± 0.09; 0.63 
Photo (solid) 0.482 0.023 87 ± 0.002; 0.38 100 ± 0.05; 0.49 
* Mean of three determinations 
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Figure 7: Base degradation spectra in zero order (A) and first derivative (B) (Phosphate pH 2.0) 
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Figure 8: Photo degradation spectra in zero order (A) and first derivative (B) (Phosphate pH 2.0) 
The developed methods were applied for the quantification of Luliconazole in creams and the assay obtained was within the 
limits which shows there is no interference from the excipients. The spectra are given in figure 9.  
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Figure 9: Overlain spectra for Assay in zero order (A) and first order derivative (B) 
Table 7: Assay of formulation 
Formulation 
Label claim (% 
w/w) 
*Amount obtained  
(% w/w) 
*Assay ± SD 
LULIFIN 
Cream 
(by sun pharma) 
1  0.98  98.5 ± 0.85 
* Mean of three determinations 
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Table 8: Optical characteristics and validation parameter of Luliconazole 
PARAMETERS 
OBTAINED VALUES 
0.1N HCl 0.1N HCl 
Phosphate buffer, 
pH 2.0 
Phosphate buffer, 
pH 2.0 
D0 D1 D0 D1 
λmax/Minima, nm 294 315 294 317 
Beer’s Law limit (μg/mL) 2-30μg/mL 2-30μg/mL 10-30μg/mL 10- 30μg/mL 
Sandell’s sensitivity 
(μg/cm²/0.001 AU) 
0.016 - 0.017 - 
Molar extinction 
Coefficient  
(L.mole-1.cm-1) 
17700 - 17700 - 
Regression equation 
(y=mx+c)* 
0.0504x+0.0102 0.0025x+0.0002 0.0637x+0.0181 0.0025x+0.0006 
Correlation  
co-efficient, R2 
0.9991 0.9991 0.999 0.999 
LOD (μg/mL) 0.01 - 0.01 - 
LOQ (μg/mL) 0.03 - 0.04 - 
 
CONCLUSION 
Two simple, precise and accurate UV spectroscopic methods 
methods have been proposed for the estimation of 
Luliconazole in bulk. These methods were found to be 
economical and could also predict the stability aspects of the 
drug in a broader sense and so can be conveniently used for 
the routine analysis of Luliconazole in dosage form. 
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